KOD vs. CNTA, XENE, CGON, QURE, RARE, APLS, IMVT, GMTX, OGN, and MOR
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Gemini Therapeutics (GMTX), Organon & Co. (OGN), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.
Kodiak Sciences vs. Its Competitors
Kodiak Sciences (NASDAQ:KOD) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
In the previous week, Kodiak Sciences had 5 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for Kodiak Sciences and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.70 beat Kodiak Sciences' score of 0.63 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.
Centessa Pharmaceuticals' return on equity of -40.39% beat Kodiak Sciences' return on equity.
Kodiak Sciences has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Kodiak Sciences presently has a consensus price target of $13.20, indicating a potential upside of 5.77%. Centessa Pharmaceuticals has a consensus price target of $32.38, indicating a potential upside of 44.47%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Kodiak Sciences.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Kodiak Sciences has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Centessa Pharmaceuticals beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KOD) was last updated on 10/15/2025 by MarketBeat.com Staff
